Royalty Pharma plc (RPRX) Cash Flow Statement
Royalty Pharma plc (RPRX) generated $3.0B of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of $3.0B, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RPRXRoyalty Pharma plcFollow RPRX — free
—
Price chart with a free account
- Market cap
- 36.7B
- P/E TTM
- 34.0
- Dividend yield
- 1.1%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.03 | 2.02 | 2.14 | 2.99 | 2.77 | 2.49 | 2.98 | |
| Capital expenditure | — | — | — | — | 0.00 | 0.00 | -0.00 | |
| Free cash flow | — | — | — | — | 2.77 | 2.49 | 2.98 | |
| Dividends paid | 0.11 | 0.29 | 0.33 | 0.36 | 0.38 | 0.38 | — | |
| Share repurchases | 0.00 | 0.00 | 0.00 | 0.30 | 0.23 | 1.23 | — | |
| Stock-based compensation | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | — |
USD billions · SEC XBRL
Royalty Pharma plc — questions
- What is Royalty Pharma plc's operating cash flow?
- $3.0B over the twelve months to 2026-06-30.
- How much does Royalty Pharma plc spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Royalty Pharma plc's free cash flow?
- $3.0B over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Royalty Pharma plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.